Looking ahead, novel approaches such as bi-specific antibody therapies [12,13] and third-generation BTK inhibitors hold promise for tackling difficult cases like Richter’s transformation and heavily pre-treated CLL [14,15]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.